A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study (Q34098873)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

0 references

author name string

L J Aronne

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

S Tonstad

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

M Moreno

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

I Gantz

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

N Erondu

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

S Suryawanshi

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

C Molony

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

S Sieberts

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J Nayee

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A G Meehan

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

D Shapiro

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

S B Heymsfield

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

K D Kaufman

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J M Amatruda

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

16 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

International Journal of Obesity

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

919-935

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The role of the endocannabinoid system in the control of energy homeostasis.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Endocannabinoid signaling system and brain reward: emphasis on dopamine

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agoni

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The PHQ-9: validity of a brief depression severity measure

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Development of a brief measure to assess quality of life in obesity.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Waist Circumference and Cardiometabolic Risk: a Consensus Statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes As

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The gastrointestinal pharmacology of cannabinoids: an update.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

SR141716A is an inverse agonist at the human cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

21 January 2018

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.21

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/IJO.2010.21

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34098873&oldid=2196241956"